These awards aim to empower academic researchers by providing the critical funding and strategic guidance needed to overcome the “valley of death” in drug development — helping transition innovative therapeutics from the lab to patients. The 2026 global request is for proposals on Bridging Research and Innovation in Drug Development Grants (BRIDGe). These awards aim to empower academic researchers by providing the critical funding and strategic guidance needed to overcome the “valley of death” in drug development — helping transition innovative therapeutics from the lab to patients. The 2026 BRIDGe RFP supports therapeutic areas including brain health, pediatrics, and rare and orphan diseases.Eligible therapeutic modalities include:Small moleculesProtein-based therapeutics (PBTs), including peptides, proteins, conventional, bivalent or trivalent antibodies, peptide-drug conjugates (PDCs), and antibody–drug conjugates (ADCs)In vivo gene-based therapies Deadline for applications 16 Mar, 2026 Further information and application
